Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Invested Capital (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Invested Capital for 4 consecutive years, with $411.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 17.58% to $411.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $411.4 million, a 17.58% decrease, with the full-year FY2024 number at $510.5 million, up 116.08% from a year prior.
  • Invested Capital was $411.4 million for Q3 2025 at Centessa Pharmaceuticals, down from $454.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $510.5 million in Q4 2024 to a low of $215.2 million in Q1 2024.
  • A 4-year average of $369.9 million and a median of $372.9 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: tumbled 38.92% in 2023, then soared 130.29% in 2025.
  • Centessa Pharmaceuticals' Invested Capital stood at $336.2 million in 2022, then decreased by 29.72% to $236.2 million in 2023, then surged by 116.08% to $510.5 million in 2024, then fell by 19.41% to $411.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Invested Capital are $411.4 million (Q3 2025), $454.5 million (Q2 2025), and $495.5 million (Q1 2025).